. "K\u0159en, V." . "Kazdov\u00E1, Ludmila" . "Pharmacogenomics" . . "RIV/00023001:_____/08:00001764" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "Hamet, P." . "Corbeil, G." . "1462-2416" . "K\u0159enov\u00E1, D." . "15"^^ . "Oliyarnyk, Olena" . . . "Pharmacogenomics of metabolic effects of rosiglitazone" . "386454" . "Tremblay, J." . "Pharmacogenomics of metabolic effects of rosiglitazone"@en . "9" . . "We compared the effect of rosiglitazone (RSG) in adult male rats of two genetically defined models of metabolic syndrome, the PD/Cub and BN.SHR4 rat strains, in contrast to their insulin-sensitive, normolipidemic counterpart, the Brown Norway strain. All rats were fed high-fat diet for the period of four weeks, the experimental groups received RSG (0.4mg/100g body weight) during the last two weeks of HFD-feeding. The mass and the sensitivity of visceral adipose tissue to insulin-stimulated lipogenesis increased with RSG treatment only in PD, corresponding with significant increase in expression of prostaglandin D2 synthase. The glucose tolerance was enhanced in all strains. The genes with genotype-specific expression change included aquaporin 9, ADAM metallopeptidase domain 7, catechol-O-methyl transferase and carnitine palmitoyltransferase 1B. In conclusion, RSG effects on lipid deposition and insulin sensitivity of peripheral tissues were largely dependent on the diet-modulated, pharmacogenomic i"@en . . "Pharmacogenomics of metabolic effects of rosiglitazone" . "9"^^ . "\u0160eda, Ond\u0159ej" . "2" . . . "We compared the effect of rosiglitazone (RSG) in adult male rats of two genetically defined models of metabolic syndrome, the PD/Cub and BN.SHR4 rat strains, in contrast to their insulin-sensitive, normolipidemic counterpart, the Brown Norway strain. All rats were fed high-fat diet for the period of four weeks, the experimental groups received RSG (0.4mg/100g body weight) during the last two weeks of HFD-feeding. The mass and the sensitivity of visceral adipose tissue to insulin-stimulated lipogenesis increased with RSG treatment only in PD, corresponding with significant increase in expression of prostaglandin D2 synthase. The glucose tolerance was enhanced in all strains. The genes with genotype-specific expression change included aquaporin 9, ADAM metallopeptidase domain 7, catechol-O-methyl transferase and carnitine palmitoyltransferase 1B. In conclusion, RSG effects on lipid deposition and insulin sensitivity of peripheral tissues were largely dependent on the diet-modulated, pharmacogenomic i" . . . . "3"^^ . . . "Rosiglitazone; metabolic syndrome; lipogenesis; pharmacogenomic interaction"@en . "[A98EF3123DC1]" . . . "\u0160edov\u00E1, L." . "Pharmacogenomics of metabolic effects of rosiglitazone"@en . "Faramkogenomika metabolick\u00FDch \u00FA\u010Dink\u016F rosiglitazonu"@cs . . . "Faramkogenomika metabolick\u00FDch \u00FA\u010Dink\u016F rosiglitazonu"@cs . "000257993100002" . . "RIV/00023001:_____/08:00001764!RIV09-MZ0-00023001" . "P(NR8495), Z(MSM0021620807)" . . . "Byl porovn\u00E1n \u00FA\u010Dinek rosiglitazonu (RSG) u dosp\u011Bl\u00FDch samc\u016F u dvou geneticky definovan\u00FDch model\u016F metabolick\u00E9ho syndrome, PD/Cub a BN.SHR4 a kontroln\u00EDho insulin senzitivn\u00EDho kmene Brown Norway. Potkani byli krmeni vysokotukovou dietou po dobu 4 t\u00FDdn\u016F, experiment\u00E1ln\u00ED skupina dost\u00E1vala RSG v d\u00E1vce 0,4mg/100g t\u011Blesn\u00E9 hmotnosti. RGG zvy\u0161oval senzitivitu tukov\u00E9 tk\u00E1n\u011B k \u00FA\u010Dinku inzulinu u PD potkan\u016F, kter\u00E1 byla spojena se vy\u0161\u0161\u00ED expres\u00ED prostaglandin D2 synt\u00E1zy. RSG pozitivn\u011B ovlivnil gluk\u00F3zovou tolerance u v\u0161ech srovn\u00E1van\u00FDch kmen\u016F. RSG zv\u00FD\u0161il expresi gen\u016F pro aquaporin 9, ADAM metallopeptid\u00E1zu, catechol-O-methyl transfer\u00E1zu and carnitine palmitoyltransfer\u00E1zu 1B.Vliv RSG byl z\u00E1visl\u00FD na farmakogenomick\u00E9 interakci."@cs .